Related references
Note: Only part of the references are listed.Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cancer immunotherapy: the beginning of the end of cancer?
Sofia Farkona et al.
BMC MEDICINE (2016)
Single-agent maintenance therapy for advanced non-small cell lung cancer (NSCLC): a systematic review and Bayesian network meta-analysis of 26 randomized controlled trials
Qinxue Wang et al.
PEERJ (2016)
Adherence to diabetes medication: a systematic review
I. Krass et al.
DIABETIC MEDICINE (2015)
A systematic literature review of methodologies used to assess medication adherence in patients with diabetes
Sarah Clifford et al.
CURRENT MEDICAL RESEARCH AND OPINION (2014)
ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
Bruce E. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer
Jyoti D. Patel et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
Luis G. Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line
N. B. Leighl
CURRENT ONCOLOGY (2012)
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
Luis Paz-Ares et al.
LANCET ONCOLOGY (2012)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Tudor Ciuleanu et al.
LANCET (2009)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
